ISM1 and cancer: This is the first study to find that ISM1 is associated with multiple important cancer-related pathways, especially EMT, and multiple important immunosuppressive signaling pathways, which provides us with evidence supporting application of ISM1 inhibitors in CRC immunotherapy.